U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Anil Patri
  1. National Center for Toxicological Research

Anil Patri Ph.D.

Anil Patri

Director, Nanotechnology Core Facility — Office of Scientific Coordination

Dr. Anil Patri
Anil Patri, Ph.D.

(870) 543-7391
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigator page


About  |  Publications  |  Lab Members
 


Background


Dr. Anil Kumar Patri received his Bachelor of Science degree in chemistry and biology from Osmania University, India, in 1987. After working with Astra IDL (Astra Zeneca) for a year, he obtained his Master of Science in organic chemistry from Aligarh Muslim University, India. He then worked as a lecturer in chemistry before moving to the U.S. and earning his Ph.D. in chemistry from the University of South Florida where he worked on the synthesis of novel nano-sized dendritic polymeric material. Dr. Patri received the “Provost’s Award for Outstanding Research” and the “Tharpe Award for Teaching” while in graduate school. He then pursued postdoctoral research at the University of Michigan Medical School, Center for Biologic Nanotechnology, developing multifunctional targeted drug-delivery and imaging systems using nanomaterial. While at Michigan, he was a co-principal investigator on a number of federally funded grants working in a collaborative interdisciplinary team environment.

Dr. Patri moved to the National Cancer Institute’s Nanotechnology Characterization Laboratory (NCL) in 2005. There he established the Physico-Chemical Characterization Facility and served as deputy director and principal scientist. In a decade-long tenure at NCL, he worked on clinical translation of promising cancer nanomedicines and also oversaw the preclinical assessment of over 85 projects with proof-of-principle efficacy for cancer with a multidisciplinary research team. Based on this experience, he co-developed and taught courses with NCL staff on the lessons learned and pitfalls to avoid during the preclinical development of nanomedicines intended for cancer. He closely worked with industry, academia, and government-agency collaborators in this rewarding work that lead to ten collaborator’s products in clinical trials. Dr. Patri was a guest researcher at the National Institute of Standards and Technology (NIST) from 2006-2014 and co-led the development of the first “Nanosized Gold Reference Material Standards" with NIST colleagues. He served on many editorial and advisory boards, Small Business Innovation Research (SBIR) grant evaluation committees, and site visits for NCI-funded programs.  He continues to serve on the American Society for Testing and Materials (ASTM) Committee E56 on Nanotechnology.

Dr. Patri was recruited to direct the NCTR staff and research conducted by the NCTR/Office of Regulatory Affairs (ORA) Nanotechnology Core Facility (NanoCore) and was appointed Chair of the Nanotechnology Task Force in the FDA's Office of the Commissioner. He serves on the National Nanotechnology Initiative’s (NNI) Nanoscale Science, Engineering, and Technology Subcommittee and the Nanotechnology Environmental and Health Implications (NEHI) Interagency Working Group of the NNI. Dr. Patri also serves as the co-chair of the US-EU Communities of Research on Characterization. He has co-authored more than 65 publications, book chapters, and reviews.


Research Interests


Dr. Patri’s group conducts regulatory-science research with a focus on nanomaterial characterization, structure activity, and stability studies that help to determine the nanomaterial’s impact on safety and efficacy. Dr. Patri and his laboratory members are pursuing collaborative consensus standards development that can help regulatory agencies and industry.

The Nanocore was established as an FDA collaborative resource between NCTR and ORA. Nanocore staff members from both NCTR and ORA conduct annual hands-on training sessions for reviewers from FDA product centers. The labs are well-equipped with extensive state-of-the-art instrumentation for nanomaterial assessment, including:

  • Scanning and Transmission Electron Microscopes equipped with EDS detectors
  • Specialized Field-Emission SEM with 3-View capability
  • Low Voltage Electron Microscope
  • Atomic Force Microscopes
  • Optical, Confocal Raman, and Hyperspectral Imaging instruments
  • Chromatography, Dynamic, Static and X-ray Scattering instruments
  • Asymmetric, Centrifugal Field Flow Fractionation instruments
  • Instruments with ICP-MS, UV, Fluorescence, Charged Aerosol, and Evaporative Light Scattering Detectors
  • Thermogravimetric Analysis instruments
  • Differential Scanning Calorimetry instruments.


Current major collaborative projects include:

  •  Investigation into physico-chemical attributes of nanomaterial and their influence on radiation enhancement
  • Standards development for nanomaterial characterization and in vitro assessment
  • Physiologically based pharmacokinetic analysis of liposomal drug formulations
  • Characterization and methods development for nanomaterial assessment
  • Effect of nanomaterial on stem-cell differentiation
  • Toxicity of nanomaterial in feminine-hygiene products
  • Detection, identification, characterization and quantitation of various attributes of nanomaterial in pristine state and in complex matrices
  • Investigation of nanomaterial in sunscreens
  • Biodistribution of gladolinium imaging agents
  • Genotoxicity standards of nanomaterial
  • Nanomaterial in dental composites and their effects on microbiota
  • Nanoparticle permeability through the gastrointestinal surface
  • Epigenetic effects of nanomaterial

 

BACK TO TOP


Professional Societies/National and International Groups


Global Summit for Regulatory Science 2015
Nano Working Group
Co-Chair
2015

Global Summit for Regulatory Science 2016
Co-Chair
2016

Indo-US Science and Technology Forum
Emerging Material and Manufacturing Working Group
Member
2016 – Present

International Congress on Nanobiomedicine
Scientific Advisory Committee
Member
2009 – Present

Molecular Pharmaceutics
Editorial Advisory Board
2008 – Present

Special Issue on “Biological Applications of Dendrimers”
Editor
2012

Nanotechnology for Healthcare Conference
Co-Chair
2015

National Cancer Institute — Frederick
Chemistry and Structural Biology Faculty
Faculty member
2005 – 2014

Grant Proposal Review Panels for SBIR
Member
2012 – 2013

National Institutes of Health
Image Guided Drug Delivery Initiative (IGDD)
Panel Member
2012 – 2014

Image Guided Targeted Delivery (IGTD)
Panel Member
2013 – 2014

Nanotechnology Special Interest Group (NanoSIG)
Member
2011 – 2014 

NIH Grant Review Panel
Member
2016

National Nanotechnology Initiative
Nanoscale Science, Engineering, and Technology Subcommittee
FDA Representative and Member
2015 – Present

Nanotechnology Environmental and Health Implications Interagency Working Group
FDA Representative and Member
2015 – Present

Team Grants in Science and Technology
Panel Member
2012

Translation of Nanotechnology in Cancer Consortium
Member
2011 – 2014 

US-EU Communities of Research for Nanomaterial Characterization
Co-Chair
2015 – Present

Wiley’s WIREs Nanomedicine and Nanobiotechnology
Associate Editor 
2013 – Present

 


 

BACK TO TOP


Select Publications

Publication titles are linked to text abstracts on PubMed.

Repetitive Application of Sunscreen Containing Titanium Dioxide Nanoparticles on Human Skin.
Coelho SG, Patri AK, Wokovich AM, McNeil SE, Howard PC, Miller SA.
JAMA Dermatol. 2016 Apr;152(4):470-2. 
 

Protein Corona Composition Does Not Accurately Predict Hematocompatibility of Colloidal Gold Nanoparticles.
Dobrovolskaia MA, Neun BW, Man S, Ye X, Hansen M, Patri AK, Crist RM, McNeil SE.
Nanomedicine. 2014 Oct;10(7):1453-63. doi: 10.1016/j.nano.2014.01.009.
 

Inhibition of Phosphoinositol 3 Kinase Contributes to Nanoparticle-Mediated Exaggeration of Endotoxin-Induced Leukocyte Procoagulant Activity.
Ilinskaya AN, Man S, Patri AK, Clogston JD, Crist RM, Cachau RE, McNeil SE, Dobrovolskaia MA.
Nanomedicine (Lond). 2014 Jul;9(9):1311-26.
 

Assessing the Barriers to Image-Guided Drug Delivery.
Lanza GM, Moonen C, Baker JR Jr, Chang E, Cheng Z, Grodzinski P, Ferrara K, Hynynen K, Kelloff G, Lee YE, Patri AK, Sept D, Schnitzer JE, Wood BJ, Zhang M, Zheng G, Farahani K.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Jan-Feb;6(1):1-14.
 

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment.
Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank KM, Belkaid Y, Trinchieri G, Goldszmid RS.
Science. 2013 Nov 22;342(6161):967-70.
 

A Novel Gadolinium-Based Trimetasphere Metallofullerene for Application as a Magnetic Resonance Imaging Contrast Agent.
Adiseshaiah P, Dellinger A, MacFarland D, Stern S, Dobrovolskaia M, Ileva L, Patri AK, Bernardo M, Brooks DB, Zhou Z, McNeil S, Kepley C.
Invest Radiol. 2013 Nov;48(11):745-54.
 

Biotargeted Nanomedicines for Cancer: Six Tenets Before You Begin.
Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ.
Nanomedicine (Lond). 2013 Feb;8(2):299-308.
 

Common Pitfalls in Nanotechnology: Lessons Learned from NCI's Nanotechnology Characterization Laboratory.
Crist RM, Grossman JH, Patri AK, Stern ST, Dobrovolskaia MA, Adiseshaiah PP, Clogston JD, McNeil SE.
Integr Biol (Camb). 2013 Jan;5(1):66-73.
 

Challenges and Opportunities in the Advancement of Nanomedicines.
Wei A, Mehtala JG, Patri AK.
J Control Release. 2012 Dec 10;164(2):236-46.
 

Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance.
Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, Nel A, Panaro NJ, Grodzinski P.
Clin Cancer Res. 2012 Jun 15;18(12):3229-41.
 

Nanoparticle Size and Surface Charge Determine Effects of PAMAM Dendrimers on Human Platelets In Vitro.
Dobrovolskaia MA, Patri AK, Simak J, Hall JB, Semberova J, De Paoli Lacerda SH, McNeil SE.
Mol Pharm. 2012 Mar 5;9(3):382-93. doi: 10.1021/mp200463e.
 

Dendrimer-Induced Leukocyte Procoagulant Activity Depends on Particle Size and Surface Charge.
Dobrovolskaia MA, Patri AK, Potter TM, Rodriguez JC, Hall JB, McNeil SE.
Nanomedicine (Lond). 2012 Feb;7(2):245-56.
 

Dendronized Bi-2-Quinoline Ligands and Their Metal Complexes: Dendron Synthesis and Metalloassembly.
Patri, A, Moorefield, CN, Newkome, GR.
Heterocycles. 2012; 84, (2): 1023-1032.
 

Newkome-Type Dendron Stabilized Gold Nanoparticles: Synthesis, Reactivity, and Stability.
Cho TJ, Zangmeister RA, Maccuspie RI, Patri AK, Hackley VA.
Chem Mater. 2011 May 24;23(10):2665-2676.
 

Lipid Component Quantitation by Thin Layer Chromatography.
Clogston JD, Patri AK.
Methods Mol Biol. 2011;697:109-17.
 

Detecting and Measuring Free Gadolinium in Nanoparticles for MRI Imaging.
Clogston JD, Patri AK.
Methods Mol Biol. 2011;697:101-8.
 

Sterilization of Silver Nanoparticles Using Standard Gamma Irradiation Procedure Affects Particle Integrity and Biocompatibility.
Zheng J, Clogston JD, Patri AK, Dobrovolskaia MA, McNeil SE.
J Nanomed Nanotechnol. 2011 Oct 25;2011(Suppl 5):001. 
 

SEM X-Ray Microanalysis of Nanoparticles Present in Tissue or Cultured Cell Thin Sections.
Zheng J, Nagashima K, Parmiter D, de la Cruz J, Patri AK.
Methods Mol Biol. 2011;697:93-9.
 

Biological Tissue and Cell Culture Specimen Preparation for TEM Nanoparticle Characterization.
Nagashima K, Zheng J, Parmiter D, Patri AK.
Methods Mol Biol. 2011;697:83-91.
 

Chromatographic Methods for the Quantification of Free and Chelated Gadolinium Species in MRI Contrast Agent Formulations.
Cleveland D, Long SE, Sander LC, Davis WC, Murphy KE, Case RJ, Rimmer CA, Francini L, Patri AK.
Anal Bioanal Chem. 2010 Dec;398(7-8):2987-95.
 

Energy Dispersive X-Ray Analysis of Titanium Dioxide Nanoparticle Distribution after Intravenous and Subcutaneous Injection in Mice.
Patri A, Umbreit T, Zheng J, Nagashima K, Goering P, Francke-Carroll S, Gordon E, Weaver J, Miller T, Sadrieh N, McNeil S, Stratmeyer M.
J Appl Toxicol. 2009 Nov;29(8):662-72.
 

BACK TO TOP

Lab Members


Contact information for all lab members:
(870) 543-7391
NCTRResearch@fda.hhs.gov

Kal’e M. Carlisle
Management Analyst

Jessie Collins
Biology Laboratory Technician

Sureshbabu Dadiboyena, Ph.D.
Commissioner’s Fellow

Tariq Fahmi, MD, Ph.D.
Staff Fellow

Suman Ghorai, Ph.D.
ORISE Fellow

Nathan Koonce, Ph.D.
Staff Fellow

Udaya Nasini, Ph.D.
ORISE Fellow

Angel Paredes, Ph.D.
Research Biologist

Sunil Ramasahayam, Ph.D.
ORISE Fellow

Xian Wu, Ph.D.
ORISE Fellow

 

 

BACK TO TOP

 


Contact Information
Anil Patri
(870) 543-7391
Expertise
Approach